Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
Researchers are studying MDMA mostly as part of a therapy program where the drug is given together with lots of preparation and follow-up counseling. The clearest evidence so far is for treating post-traumatic stress disorder (PTSD). For sadness or general low mood, the research is much smaller and still early. Studies and reviews say MDMA shows promise, but we do not yet have strong, broad proof that it reliably helps ordinary depression. Scientists also agree on important limits. Most trials are small, they happen in tightly controlled medical settings, and many groups of people (for example, people of color) are underrepresented. Scientists say more large, careful studies are needed to know how well MDMA works for low mood, who it helps, and what risks might show up later on.
Researchers pooled results from 29 human studies that measured blood levels of a protein called brain-derived neurotrophic factor, or BDNF, after people received so-called psychoplastogen drugs such as ketamine or psychedelics. They found no clear change in blood BDNF after these drugs. The authors say this does not prove the…
